FDA records linked by MedtechLedger show one 510(k) submission associated with Medical Components, Inc. in the retrieved collection: K260080, received 12 January 2026 and decided 9 October 2026 as Substantially Equivalent. The filing covers the Pro-Line XL Power Injectable Central Venous Catheter and Pro-Line XL Tunneler, classified under 21 CFR 880.5970 and product code LJS in the General Hospital panel. The applicant address on the FDA record is in Harleysville, Pennsylvania; that is a filing address, not a verified headquarters. [1][2][6]

The K260080 clearance and its scope

The FDA 510(k) record lists K260080 as a Traditional premarket notification, reviewed by FDA rather than a third party, with no combination product status and no authorized predetermined change control plan. The decision description is Substantially Equivalent, dated 9 October 2026, with a Summary statement indicated. The device is catalogued under product code LJS and regulation number 880.5970, described in the openFDA fields as a catheter, intravascular, therapeutic, long-term greater than 30 days, device class 2. [1][2]

The submission date recorded by FDA is 12 January 2026, and the decision date is 9 October 2026. The advisory committee and review panel are both listed as General Hospital (HO). The record names Medical Components, Inc. as applicant and Elizabeth Greene as contact, with the address 1499 Delp Dr., Harleysville, PA 19438. [1][2][6]

Documented product identity

The cleared device name pairs two items: the Pro-Line XL Power Injectable Central Venous Catheter and the Pro-Line XL Tunneler. A GUDID entry published 6 November 2026 identifies a specific configuration, model and catalog number PL0920201, described as a 9.5F x 45cm dual lumen Pro-Line XL power injectable central venous catheter with a cuff at 2cm and a basic introducer set. That entry lists the company as Medical Components, Inc., marks the device as in commercial distribution, MR Conditional, prescription-only, sterile and single use. [1][5]

Medcomp's own product page for the Pro-Line line lists lumen options of single, dual and triple, lengths of 55cm, 60cm and 7F, 6F and 5F French sizes, an injection rating of 5cc/sec at 300psi, and cuff locations at 2cm or 5cm. The page states that the product may not be available in all markets and directs inquiries to sales representatives. These are manufacturer-published specifications for the Pro-Line family, not a restatement of the K260080 clearance scope. [4]

Applicant, brand and published documentation

Medical Components, Inc. is the legal applicant on the FDA filing, while Medcomp is the name used across the manufacturer's catalog and product pages. The catalog describes Medcomp as developing, manufacturing, marketing and supporting vascular access devices and accessories, and describes itself as one of the world's largest manufacturers of dialysis and centrally terminating venous catheters. Those characterizations come from the manufacturer's published catalog, not from FDA. No parent company, ownership structure or corporate website is verified in the retrieved records. [3][4]

The catalog's contents also reference adjacent accessory categories, including probe cover kits, vein picks, catheter extension repair clamps, repair kits and safety Huber needle infusion sets. These appear as catalog sections rather than as items tied to the K260080 filing. [3]

What the collection does and does not show

The retrieved collection contains one linked 510(k) record, with a decision count of one Substantially Equivalent and a sample decision count of one for the same record. These figures describe the retrieved filings as of the snapshot date and are not measures of total company sales, total portfolio size or safety performance. No recall records appear in the retrieved sample. [1]

The records do not establish clinical performance, comparative effectiveness, certification status or customer relationships. The Innolitics record notes that certain work was not performed to support substantial equivalence, without further detail in the retrieved excerpt. Questions about indications, patient selection or use should be directed to the manufacturer's instructions for use and FDA documentation. [6][4]